PK/PD Modeling & Simulation

Think Global, Act Local: Supporting Orphan Drug Development in NJ

Dana Cohen

You could say that I’m a Jersey Girl. Having lived all my life in the Garden State, it’s important to me to help give back to the New Jersey community that is home to our Princeton headquarters. So, I’m really proud that Certara has supported the approval of several orphan drugs for rare diseases, one […]

Read More
Topics: PK/PD Modeling & Simulation

Motesanib’s Promise & Peril: Population PK Modeling an Anticancer Drug

Nathalie Gosselin

When thinking about the challenges of oncology drug development, I recall the advice of the 6th century BCE military strategist, Sun Tzu: If you know the enemy and know yourself, you need not fear the result of a hundred battles. If you know yourself, but not the enemy, for every victory gained you will also […]

Read More
Topics: PK/PD Modeling & Simulation

Gaining FDA Support for a Prognostic Biomarker, Giving Patients Hope

Samer Mouksassi

As a clinician scientist, I get really excited about helping sponsors develop new treatments for patients. For some diseases, the lack of a validated prognostic biomarker is an impediment to developing effective treatments. In this blog post, I’ll discuss how we worked with the Critical Path Institute (C-Path) Polycystic Kidney Disease Outcomes Consortium to gain […]

Read More
Topics: Uncategorized

How to Explain the Value of Biosimulation to Your Grandma

Suzanne Minton

As most scientists can attest, it’s not always easy to communicate the importance of your work to non-scientists. I personally experienced this when my fiercely intelligent grandmother, a former elementary school teacher, asked to read a copy of my dissertation. When I asked her what she thought of it, I realized that her understanding of […]

Read More
Topics: Clinical Transparency & Disclosure
Learn More LinkedIn Twitter Facebook Email